**Overzicht publicaties**

Sandra Bakker
Internist-oncoloog

1. PMID: 28890811

[Tumor stage in patients operated for rectal cancer: a comparison of the pre-operative MR and the resection specimen, with specific attention to the effect of neo-adjuvant radiotherapy.](https://pubmed.ncbi.nlm.nih.gov/28890811/)

van Eeghen EE, Bakker SD, Fransen G, Flens MJ, Loffeld RJLF.

J Gastrointest Oncol. 2017 Aug;8(4):625-628. doi: 10.21037/jgo.2017.04.05.PMID: 28890811

**Free PMC article.**

2. PMID: 26697191

[Impact of age and comorbidity on survival in colorectal cancer.](https://pubmed.ncbi.nlm.nih.gov/26697191/)

van Eeghen EE, Bakker SD, van Bochove A, Loffeld RJ.

J Gastrointest Oncol. 2015 Dec;6(6):605-12. doi: 10.3978/j.issn.2078-6891.2015.070.PMID: 26697191

**Free PMC article.**

3. PMID: 27284462

[Outcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study.](https://pubmed.ncbi.nlm.nih.gov/27284462/)

van Eeghen EE, den Boer F, Bakker SD, Loffeld RJ.

J Gastrointest Oncol. 2016 Jun;7(3):321-5. doi: 10.21037/jgo.2015.10.08.PMID: 27284462

**Free PMC article.**

4. PMID: 27347548

[High Risk Stage 2 and Stage 3 Colon Cancer, Predictors of Recurrence and Effect of Adjuvant Therapy in a Nonselected Population.](https://pubmed.ncbi.nlm.nih.gov/27347548/)

van Eeghen EE, Bakker SD, van Bochove A, Loffeld RJ.

Int Sch Res Notices. 2015 Jun 21;2015:790186. doi: 10.1155/2015/790186. eCollection 2015.PMID: 27347548

**Free PMC article.**

5. PMID: 35442755

[Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.](https://pubmed.ncbi.nlm.nih.gov/35442755/)

Vliek SB, Noordhoek I, Meershoek-Klein Kranenbarg E, van Rossum AGJ, Dezentje VO, Jager A, Hokken JWE, Putter H, van der Velden AWG, Hendriks MP, Bakker SD, van Riet YEA, Tjan-Heijnen VCG, Portielje JEA, Kroep JR, Nortier JWR, van de Velde CJH, Linn SC.

J Clin Oncol. 2022 Sep 1;40(25):2934-2945. doi: 10.1200/JCO.21.00311. Epub 2022 Apr 20.PMID: 35442755 Clinical Trial.

6. PMID: 40035673

[The Diagnostic Accuracy of 18F-FDG PET and 18F-FES PET for Staging Grade 1-2 Estrogen Receptor-Positive Breast Cancer.](https://pubmed.ncbi.nlm.nih.gov/40035673/)

Knip JJ, Iqbal R, Bonjer EC, Mammatas LH, van Zweeden AA, Perin P, Teunissen JJM, Diepenhorst GMP, Schijf LJ, Bakker SD, Schoenmakers N, van der Velde S, Barbé E, Duvivier K, Konings IR, Zwezerijnen GJC, Windhorst AD, Boellaard R, Oprea-Lager DE, Menke-van der Houven van Oordt CW.

Radiology. 2025 Mar;314(3):e241850. doi: 10.1148/radiol.241850.PMID: 40035673

7. PMID: 23928661

[Critical weight loss is a major prognostic indicator for disease-specific survival in patients with head and neck cancer receiving radiotherapy.](https://pubmed.ncbi.nlm.nih.gov/23928661/)

Langius JA, Bakker S, Rietveld DH, Kruizenga HM, Langendijk JA, Weijs PJ, Leemans CR.

Br J Cancer. 2013 Sep 3;109(5):1093-9. doi: 10.1038/bjc.2013.458. Epub 2013 Aug 8.PMID: 23928661

**Free PMC article.**

8. PMID: 36228963

[Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.](https://pubmed.ncbi.nlm.nih.gov/36228963/)

Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators.

Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10.PMID: 36228963

**Free PMC article.** Clinical Trial.

9. PMID: 38588682

[MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.](https://pubmed.ncbi.nlm.nih.gov/38588682/)

van der Voort A, Louis FM, van Ramshorst MS, Kessels R, Mandjes IA, Kemper I, Agterof MJ, van der Steeg WA, Heijns JB, van Bekkum ML, Siemerink EJ, Kuijer PM, Scholten A, Wesseling J, Vrancken Peeters MTFD, Mann RM, Sonke GS; Dutch Breast Cancer Research Group.

Lancet Oncol. 2024 May;25(5):603-613. doi: 10.1016/S1470-2045(24)00104-9. Epub 2024 Apr 5.PMID: 38588682 Clinical Trial.

10. PMID: 39206149

[Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.](https://pubmed.ncbi.nlm.nih.gov/39206149/)

Opdam M, van Rossum AGJ, Hoogstraat M, Bounova G, Horlings HM, van Werkhoven E, Mandjes IAM, van Leeuwen-Stok AE, Canisius S, van Tinteren H, Imholz ALT, Portielje JEA, Bos MEMM, Bakker S, Wesseling J, Kester L, van Rheenen J, Rutgers EJ, de Menezes RX, Wessels LFA, Kok M, Oosterkamp HM, Linn SC; MATADOR trialists’ group for the Dutch Breast Cancer Research Group (BOOG).

iScience. 2024 Jun 29;27(8):110425. doi: 10.1016/j.isci.2024.110425. eCollection 2024 Aug 16.PMID: 39206149

**Free PMC article.**

11. PMID: 38452438

[Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer.](https://pubmed.ncbi.nlm.nih.gov/38452438/)

de Boo LW, Jóźwiak K, Ter Hoeve ND, van Diest PJ, Opdam M, Wang Y, Schmidt MK, de Jong V, Kleiterp S, Cornelissen S, Baars D, Koornstra RHT, Kerver ED, van Dalen T, Bins AD, Beeker A, van den Heiligenberg SM, de Jong PC, Bakker SD, Rietbroek RC, Konings IR, Blankenburgh R, Bijlsma RM, Imholz ALT, Stathonikos N, Vreuls W, Sanders J, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen E, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, van der Wall E, Siesling S, Salgado R, Dackus GMHE, Hauptmann M, Kok M, Linn SC.

ESMO Open. 2024 Mar;9(3):102923. doi: 10.1016/j.esmoop.2024.102923. Epub 2024 Mar 6.PMID: 38452438

**Free PMC article.**

12. PMID: 33104921

[Feasibility and outcomes of a goal-directed physical therapy program for patients with metastatic breast cancer.](https://pubmed.ncbi.nlm.nih.gov/33104921/)

Groen WG, Ten Tusscher MR, Verbeek R, Geleijn E, Sonke GS, Konings IR, Van der Vorst MJ, van Zweeden AA, Schrama JG, Vrijaldenhoven S, Bakker SD, Aaronson NK, Stuiver MM.

Support Care Cancer. 2021 Jun;29(6):3287-3298. doi: 10.1007/s00520-020-05852-9. Epub 2020 Oct 26.PMID: 33104921

13. PMID: 38852675

[Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group.](https://pubmed.ncbi.nlm.nih.gov/38852675/)

van der Kruijssen DEW, Elias SG, van de Ven PM, van Rooijen KL, Lam-Boer J', Mol L, Punt CJA, Sommeijer DW, Tanis PJ, Nielsen JD, Yilmaz MK, van Riel JMGH, Wasowiz-Kemps DK, Loosveld OJL, van der Schelling GP, de Groot JWB, van Westreenen HL, Jakobsen HL, Fromm AL, Hamberg P, Verseveld M, Jaensch C, Liposits GI, van Duijvendijk P, Oulad Hadj J, van der Hoeven JAB, Trajkovic M, de Wilt JHW, Koopman M; CAIRO4 Working Group.

Ann Oncol. 2024 Sep;35(9):769-779. doi: 10.1016/j.annonc.2024.06.001. Epub 2024 Jun 7.PMID: 38852675

**Free article.** Clinical Trial.

14. PMID: 33046804

[Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.](https://pubmed.ncbi.nlm.nih.gov/33046804/)

Wensink GE, Elferink MAG, May AM, Mol L, Hamers PAH, Bakker SD, Creemers GJ, de Groot JWB, de Klerk GJ, Haberkorn BCM, Haringhuizen AW, Hoekstra R, Hunting JCB, Kerver ED, Mathijssen-van Stein D, Polée MB, Pruijt JFM, Quarles van Ufford-Mannesse P, Radema S, Rietbroek RC, Simkens LHJ, Tanis BC, Ten Bokkel Huinink D, Tjin-A-Ton MLR, Tromp-van Driel CS, Troost MM, van de Wouw AJ, van den Berkmortel FWPJ, van der Pas AJM, van der Velden AMT, van Dijk MA, van Dodewaard-de Jong JM, van Druten EB, van Voorthuizen T, Jan Veldhuis G, Verheul HMW, Vestjens HJHMJ, Vincent J, Kranenburg OW, Punt CJA, Vink GR, Roodhart JML, Koopman M.

Br J Cancer. 2021 Jan;124(2):399-406. doi: 10.1038/s41416-020-01076-0. Epub 2020 Oct 13.PMID: 33046804

**Free PMC article.**

15. PMID: 34965952

[Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.](https://pubmed.ncbi.nlm.nih.gov/34965952/)

Kester L, Seinstra D, van Rossum AGJ, Vennin C, Hoogstraat M, van der Velden D, Opdam M, van Werkhoven E, Hahn K, Nederlof I, Lips EH, Mandjes IAM, van Leeuwen-Stok AE, Canisius S, van Tinteren H, Imholz ALT, Portielje JEA, Bos MEMM, Bakker SD, Rutgers EJ, Horlings HM, Wesseling J, Voest EE, Wessels LFA, Kok M, Oosterkamp HM, van Oudenaarden A, Linn SC, van Rheenen J.

Clin Cancer Res. 2022 Mar 1;28(5):960-971. doi: 10.1158/1078-0432.CCR-21-1442.PMID: 34965952

**Free PMC article.**

16. PMID: 35587322

[Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature.](https://pubmed.ncbi.nlm.nih.gov/35587322/)

Opdam M, van der Noort V, Kleijn M, Glas A, Mandjes I, Kleiterp S, Hilbers FS, Kruger DT, Bins AD, de Jong PC, Schiphorst PPJBM, van Dalen T, Flameling B, Rietbroek RC, Beeker A, van den Heiligenberg SM, Bakker SD, Wymenga ANM, Oving IM, Bijlsma RM, van Diest PJ, Vermorken JB, van Tinteren H, Linn SC.

Breast Cancer Res Treat. 2022 Jul;194(2):265-278. doi: 10.1007/s10549-022-06618-z. Epub 2022 May 19.PMID: 35587322

**Free PMC article.** Clinical Trial.

17. PMID: 34799210

[Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium.](https://pubmed.ncbi.nlm.nih.gov/34799210/)

de Joode K, Tol J, Hamberg P, Cloos M, Kastelijn EA, Borgers JSW, Nuij VJAA, Klaver Y, Herder GJM, Mutsaers PGNJ, Dumoulin DW, Oomen-de Hoop E, van Diemen NGJ, Libourel EJ, Geraedts EJ, Bootsma GP, van der Leest CH, Peerdeman AL, Herbschleb KH, Visser OJ, Bloemendal HJ, van Laarhoven HWM, de Vries EGE, Hendriks LEL, Beerepoot LV, Westgeest HM, van den Berkmortel FWPJ, Haanen JBAG, Dingemans AC, van der Veldt AAM; DOCC investigators.

Eur J Cancer. 2022 Jan;160:261-272. doi: 10.1016/j.ejca.2021.10.009. Epub 2021 Oct 25.PMID: 34799210

**Free PMC article.**

18. PMID: 36820944

[Blended online learning for oncologists to improve skills in shared decision making about palliative chemotherapy: a pre-posttest evaluation.](https://pubmed.ncbi.nlm.nih.gov/36820944/)

Bos-van den Hoek DW, van Laarhoven HWM, Ali R, Bakker SD, Goosens A, Hendriks MP, Pepels MJAE, Tange D, de Vos FYFL, van de Wouw AJ, Smets EMA, Henselmans I.

Support Care Cancer. 2023 Feb 23;31(3):184. doi: 10.1007/s00520-023-07625-6.PMID: 36820944

**Free PMC article.**

19. PMID: 10139105

[Subject strengths and weaknesses of four current-awareness services on diskette.](https://pubmed.ncbi.nlm.nih.gov/10139105/)

Bakker S.

Health Libr Rev. 1992 Dec;9(4):131-7. doi: 10.1046/j.1365-2532.1992.940131.x.PMID: 10139105

**Free article.**

20. PMID: 33161241

[Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study.](https://pubmed.ncbi.nlm.nih.gov/33161241/)

de Joode K, Dumoulin DW, Tol J, Westgeest HM, Beerepoot LV, van den Berkmortel FWPJ, Mutsaers PGNJ, van Diemen NGJ, Visser OJ, Oomen-de Hoop E, Bloemendal HJ, van Laarhoven HWM, Hendriks LEL, Haanen JBAG, de Vries EGE, Dingemans AC, van der Veldt AAM; DOCC Investigators.

Eur J Cancer. 2020 Dec;141:171-184. doi: 10.1016/j.ejca.2020.09.027. Epub 2020 Oct 7.PMID: 33161241

**Free PMC article.**

21. PMID: 34613339

[Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment: The CAIRO4 Phase 3 Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34613339/)

van der Kruijssen DEW, Elias SG, Vink GR, van Rooijen KL, 't Lam-Boer J, Mol L, Punt CJA, de Wilt JHW, Koopman M; CAIRO4 Working Group.

JAMA Surg. 2021 Dec 1;156(12):1093-1101. doi: 10.1001/jamasurg.2021.4992.PMID: 34613339

**Free PMC article.** Clinical Trial.

22. PMID: 32186813

[[Vertigo as the first manifestation of ovarian cancer].](https://pubmed.ncbi.nlm.nih.gov/32186813/)

Weiland MTD, van Oosterhout WPJ, Bakker SD.

Ned Tijdschr Geneeskd. 2020 Feb 3;164:D3982.PMID: 32186813 Dutch.